Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Abiraterone
Drug ID BADD_D00014
Description Abiraterone is a derivative of steroidal progesterone and is an innovative drug that offers clinical benefit to patients with hormone refractory prostate cancer. Abiraterone is administered as an acetate salt prodrug because it has a higher bioavailability and less susceptible to hydrolysis than abiraterone itself. FDA approved on April 28, 2011.
Indications and Usage Used in combination with prednisone for the treatment of metastatic, castration-resistant prostate cancer.
Marketing Status Not Available
ATC Code Not Available
DrugBank ID DB05812
KEGG ID Not Available
MeSH ID C089740
PubChem ID 132971
TTD Drug ID D02STN
NDC Product Code 17337-0082; 30007-838; 42291-073; 60687-455; 69238-1165; 42291-024; 69238-1754; 54893-0070
Synonyms abiraterone | 17-(3-pyridyl)androsta-5,16-dien-3beta-ol | CB-7598 | CB 7598 | CB7598
Chemical Information
Molecular Formula C24H31NO
CAS Registry Number 154229-19-3
SMILES CC12CCC(CC1=CCC3C2CCC4(C3CC=C4C5=CN=CC=C5)C)O
Chemical Structure
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Dehydration14.05.05.0010.031626%
Delirium19.13.02.001--
Dementia17.03.01.001; 19.20.02.0010.010297%Not Available
Depressed level of consciousness17.02.04.002--
Depressed mood19.15.02.001--Not Available
Depression19.15.01.001--
Dermatitis23.03.04.002--Not Available
Diabetes mellitus05.06.01.001; 14.06.01.0010.027949%Not Available
Diabetes mellitus inadequate control05.06.01.004; 14.06.01.0040.002942%Not Available
Diarrhoea07.02.01.001--
Diplopia06.02.06.002; 17.17.01.005--Not Available
Discomfort08.01.08.003--Not Available
Disorientation17.02.05.015; 19.13.01.002--Not Available
Disseminated intravascular coagulation01.01.02.002; 24.01.01.0100.000959%
Disturbance in attention17.03.03.001; 19.21.02.002--
Diverticulitis07.10.02.001; 11.01.07.003--Not Available
Dizziness02.01.02.004; 17.02.05.003; 24.06.02.007--
Dizziness postural02.01.02.005; 17.02.05.004; 24.06.02.0080.001471%Not Available
Drug eruption08.01.06.015; 10.01.01.005; 23.03.05.0010.005148%Not Available
Drug hypersensitivity10.01.01.001--Not Available
Dry mouth07.06.01.0020.012503%
Dry skin23.03.03.001--
Duodenal ulcer07.04.02.0020.002206%
Dysarthria17.02.08.001; 19.19.03.001--
Dysgeusia07.14.03.001; 17.02.07.003--
Dyspepsia07.01.02.001--
Dysphagia07.01.06.0030.097820%
Dysphonia17.02.08.004; 19.19.03.002; 22.02.05.005--
Dyspnoea02.01.03.002; 22.02.01.004--
Dysuria20.02.02.0020.011032%
The 5th Page    First    Pre   5 6 7 8 9    Next   Last    Total 22 Pages